Pulse Biosciences (PLSE) Q3 2026 earnings review
Pulse Biosciences finishes its heart trial, while commercial timelines slip
Pulse Biosciences, a medical device maker testing electrical pulses to treat irregular heartbeats, finished enrolling its main US clinical trial early and nearly doubled its cash pile. Chief executive Paul LaViolette said doctors enrolled all 169 heart patients in under six months, beating the company's plan by three months. Meanwhile, the company sold $96 million of new stock, lifting cash to $189 million while quarterly sales from its thyroid tool stayed under half a million dollars.
| US catheter trial enrollment | 169 patients completed 3 months ahead of plan |
|---|---|
| Cash and marketable securities | $189.2M $101.6M last quarter after $95.8M stock sale |
| Cash used in operations | $15.3M $18.7M last quarter |
| European catheter approval outlook | Pushed back now Q4 2027 vs mid-2027 previously |
⚖️ Verdict: 🟢 Bullish
The story got better because the company removed its two biggest near-term hurdles: finishing patient sign-ups and raising enough money to reach regulatory decisions. By our math, the cash balance now covers more than three years of operating burn at the third-quarter pace. One caution: management pushed expected European catheter approval from mid-2027 to late 2027 and extended the restricted launch of its thyroid device through late 2027, delaying meaningful revenue.
The question now is whether fast trial sign-ups translate into lasting cures once patient follow-up finishes. Optimists see doctors' quick adoption as proof the catheter works well, while skeptics note that efficacy results remain blinded and the device still lacks a heart-mapping partner. One-year European follow-up data in the first quarter of 2027 will provide the first answer.
🐂 Bull Case
US Catheter Trial Enrolled Ahead of Plan
Pulse Biosciences is developing the nPulse Cardiac Catheter System, a device that uses billionth-of-a-second electrical pulses to treat atrial fibrillation (AF), an irregular heartbeat. "Pulse Biosciences delivered several major milestones since the second quarter, led by completing enrollment in our U.S. pivotal IDE study in just six months, three months ahead of plan," chief executive Paul LaViolette said.
Doctors treated 169 evaluable patients across 15 sites in the NANOPULSE-AF trial, adding 87 patients since June by our math and beating the 164-patient goal. The medical device company also plans to apply to US regulators in the fourth quarter to start a new trial for persistent AF, "extending the nPulse catheter platform to larger and more complex patient groups".
Fast enrollment matters because it starts the clock on patient follow-up sooner, which brings a US regulatory filing closer. Still, signing up patients quickly shows doctor interest during a study, not that the catheter cured their heart rhythm problems.
What to watch: twelve-month follow-up results on 100 patients from the European feasibility study in the first quarter of 2027. A high success rate there would support the device's durability while investors wait for the US trial results.
Stock Sales Double Cash to $189 Million
Because the bioelectric medicine group has almost no sales, it pays for its clinical trials by selling new shares through at-the-market (ATM) stock programs. Critics have worried that rising cash burn would force constant share sales and heavy dilution before any heart catheter reaches the market.
In the third quarter, the company raised $95.8 million in net proceeds from stock sales, lifting cash and marketable securities to $189.2 million from $101.6 million in June. Since May, it has raised over $150 million while increasing the total share count by less than 6%.
- Ending cash and marketable securities: $189.2 million, up 86% from last quarter by our math
- Estimated yearly interest income: over $7.5 million at current yields
- Remaining ATM stock-sale capacity: about $64 million
- Issued common shares: 73.3 million, up 3.6% from June by our math
This cash cushion removes near-term funding pressure because, by our math, $189.2 million covers more than 12 quarters of operating cash burn at the third-quarter rate of $15.3 million. That gives Pulse Biosciences enough money to finish patient follow-up and file for US and European approvals without needing another raise.
What to watch: shares outstanding and ATM proceeds in the fourth-quarter report. Stopping share sales now that cash sits near $190 million would show management is protecting shareholders from unnecessary dilution.
Positives this quarter didn't test
Two parts of the positive case received no new numbers in the third-quarter release.
- Catheter procedure speed and hospital economics: no procedure times or lab throughput figures were published; the first-quarter 2027 European data readout is the next chance to see them.
- Insider buying in stock offerings: management did not say whether insiders bought shares in the $95.8 million third-quarter raise, a detail the quarterly filing will show.
🐻 Bear Case
European Catheter Approval Slips to Late 2027
LaViolette said the company is now focused on preparations for launch readiness and regulatory submissions. European approval (CE Mark) for the nPulse Cardiac Catheter is supposed to be Pulse Biosciences' first commercial entry into the heart rhythm market, arriving well before US approval.
Yet the company pushed that European timeline back. The release stated that the company "continued to progress toward a CE Mark submission with anticipated CE mark approval in Q4 2027". Three months ago, management pointed to a submission in the second half of 2026 and potential approval around the middle of 2027.
The delay matters because it leaves the company with no heart catheter revenue until at least the end of 2027. Furthermore, the release made no mention of the surgical clamp CE Mark filing, which management previously promised before the end of 2026, nor did it say when the US catheter trial data will be submitted to the FDA.
What to watch: confirmation in the fourth-quarter report that the European catheter application has actually been filed. Another quarter of progressing toward a submission would push European sales into 2028.
Soft Tissue Sales Stay Under Half a Million
Vybrance is the company's percutaneous electrode system for destroying non-cancerous thyroid nodules and other soft tissue. It is the only product Pulse Biosciences currently sells, and the company completed its 100-patient PRECISE-BTN thyroid clinical study in September.
Third-quarter revenue was $395,000, up from $86,000 a year ago when the launch began, but down 9% from $434,000 in the second quarter by our math. The company said it remains in a controlled launch "within a limited customer base" and expects this restricted phase to last into the fourth quarter of 2027.
Extending the limited launch for another full year means Vybrance will not help pay for the company's clinical trials anytime soon. Until the device secures dedicated insurance reimbursement codes and a specific regulatory label, quarterly revenue is stuck below half a million dollars.
What to watch: six-month and twelve-month follow-up data from the 100-patient PRECISE-BTN thyroid study in 2027. Strong results are needed to win insurance coverage and move Vybrance out of its test phase.
Risks this quarter didn't answer
Four standing risks around clinical efficacy, partnerships and secondary trials were not addressed in the release.
- US catheter trial drug mix and efficacy: enrollment is finished, but results are blinded during follow-up and management has not disclosed how many patients qualified under loosened medication rules.
- Heart mapping partnership: after five quarters of discussing a partner for mapping integration, the release did not mention a deal.
- Competition from established catheter makers: large rivals already sell pulsed field ablation devices, a challenge that cannot be tested until nPulse reaches the market.
- Surgical clamp CE Mark and thyroid cancer study: the release gave no update on the surgical clamp European filing or the MD Anderson thyroid cancer study, both previously due by year-end 2026.
👓 Other Themes
Clinical Trial Spending Lifts Research Costs 48%
Following its March 2026 realignment to focus on the heart catheter, Pulse Biosciences shifted spending from overhead into clinical trials. Research and development expenses rose 48% from a year ago to $16.8 million (68% of total costs, up from 56% by our math), driven by trial activity and hiring. Meanwhile, selling, general and administrative expenses fell 13% to $7.6 million, and total costs excluding one-offs dropped 7% from last quarter to $19.1 million.
💲 Other KPIs
Operating cash burn fell 18% from $18.7 million in the second quarter by our math, though it remained 18% higher than the $13.0 million used a year ago. The sequential drop reflects lower overhead spending and a rise in unpaid bills at quarter-end.
The net loss narrowed from $24.7 million in the second quarter, but widened 19% from $19.4 million a year ago as clinical trial costs grew. Loss per share was $0.32, compared with $0.29 a year ago and $0.36 last quarter, helped by a higher share count and $1.2 million in interest income.
Accrued liabilities — expenses the company has recorded on its books but not yet paid in cash — rose 34% from $6.5 million in June by our math, and more than doubled from $3.6 million at the end of 2025. That buildup of unpaid clinical trial bills explains why cash burn ($15.3 million) was lower than operating expenses ($19.1 million excluding one-offs).
🔮 Guidance
Cut. The company now anticipates European regulatory approval for its heart catheter in the fourth quarter of 2027, roughly two quarters later than the mid-2027 target given last quarter. Management also dropped the specific second-half 2026 target date for submitting the application.
Unchanged. The US pivotal study for the surgical heart clamp remains on track to finish enrolling patients by the end of the first half of 2027. That schedule was previously pushed back from an original 2026 target when the company shifted priority to the catheter.
New. Pulse Biosciences plans to apply to the FDA in the fourth quarter of 2026 to begin a clinical study of its nPulse catheter in patients with persistent atrial fibrillation, a more advanced form of the heart rhythm disorder.
New. Management expects the restricted commercial launch of its Vybrance soft-tissue system to continue into the fourth quarter of 2027, keeping sales limited to existing accounts while it builds clinical data.
❓ Key Questions
Why did European catheter approval slip to late 2027?
Last quarter management expected to file for a European CE Mark in the second half of 2026 with approval around mid-2027. The new target is fourth-quarter 2027 approval, and the release gave no filing date or reason for the delay.
When will US catheter trial data reach the FDA?
NANOPULSE-AF finished enrolling 169 patients three months early in September. Investors need to know when the 12-month follow-up finishes for the last cohort and which quarter the company expects to submit its US premarket approval application.
Where do the surgical CE Mark and cancer study stand?
Prior plans called for filing the surgical clamp CE Mark application and finishing enrollment in the MD Anderson thyroid cancer study before the end of 2026. Neither milestone appeared in the third-quarter release.
Is a heart mapping partnership still in the works?
Management had discussed an electrophysiology mapping partnership for five straight quarters, yet the release made no mention of a partner. Commercializing an ablation catheter against giant incumbents without an integrated mapping partner is a major hurdle.